AIVF

Israel’s AiVF receives approval to sell its AI-driven IVF management platform in the UK

AiVF received a regulatory approval to market and sell its EMA™ product in the UK. This approval follows EMA’s EU CE marking approval, which was announced in April. AiVF’s EMA™ platform combines AI-based machine learning and computer vision to improve embryos’ implantation success rates. AiVF can predict, without the need for a biopsy, whether a given embryo is genetically suitable for transfer.

AiVF study: genetic characteristics in embryos can be identified by non-invasive AI analysis

Daniella Gilboa, CEO and Co-Founder of AiVF: "This breakthrough scientific research concluded that AiVF's EMA™ platform can automatically and reliably determine an embryo's ploidy status i.e., whether it is genetically suitable, without the need for an invasive biopsy (PGT-A) or spent media analysis. A truly contactless PGT-A”

AiVF Receives European Approval for its Cutting Edge AI based IVF Treatments